share_log

CVS Health | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

CVS Health | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

西维斯健康 | FWP:自由书写募资说明书
美股SEC公告 ·  2024/05/07 16:54

Moomoo AI 已提取核心信息

CVS Health Corporation has successfully priced a series of Senior Notes on May 7, 2024, with a total value of $5 billion. The offering includes $1 billion of 5.400% Senior Notes due in 2029, $1 billion of 5.550% Senior Notes due in 2031, $1.25 billion of 5.700% Senior Notes due in 2034, $750 million of 6.000% Senior Notes due in 2044, and $1 billion of 6.050% Senior Notes due in 2054. The notes were priced close to their principal amount and will pay semiannual interest starting December 1, 2024. The maturity dates for these notes range from June 1, 2029, to June 1, 2054. CVS Health has included optional redemption provisions for these notes, allowing the company to redeem the notes before their maturity dates under certain conditions. The offering was managed by a consortium of banks, including BOFA Securities, Inc., Barclays Capital Inc., and others. The notes have been rated Baa2 by Moody's and BBB by S&P. This strategic financial move is aimed at diversifying CVS Health's funding sources and extending its debt maturity profile.
CVS Health Corporation has successfully priced a series of Senior Notes on May 7, 2024, with a total value of $5 billion. The offering includes $1 billion of 5.400% Senior Notes due in 2029, $1 billion of 5.550% Senior Notes due in 2031, $1.25 billion of 5.700% Senior Notes due in 2034, $750 million of 6.000% Senior Notes due in 2044, and $1 billion of 6.050% Senior Notes due in 2054. The notes were priced close to their principal amount and will pay semiannual interest starting December 1, 2024. The maturity dates for these notes range from June 1, 2029, to June 1, 2054. CVS Health has included optional redemption provisions for these notes, allowing the company to redeem the notes before their maturity dates under certain conditions. The offering was managed by a consortium of banks, including BOFA Securities, Inc., Barclays Capital Inc., and others. The notes have been rated Baa2 by Moody's and BBB by S&P. This strategic financial move is aimed at diversifying CVS Health's funding sources and extending its debt maturity profile.
CVS Health Corporation已于2024年5月7日成功对一系列优先票据进行了定价,总价值为50亿美元。此次发行包括将于2029年到期的10亿美元5.400%的优先票据,2031年到期的10亿美元5.550%的优先票据,2034年到期的12.5亿美元5.700%的优先票据,2044年到期的7.5亿美元6.000%的优先票据,以及2054年到期的10亿美元6.050%的优先票据。这些票据的定价接近其本金,并将从2024年12月1日起支付半年利息。这些票据的到期日为2029年6月1日至2054年6月1日。CVS Health为这些票据提供了可选的赎回条款,允许公司在某些条件下在到期日之前赎回票据。此次发行由包括美银证券公司、巴克莱资本公司等在内的银行财团管理。这些票据被穆迪评为Baa2,标准普尔将BBB评为Baa2。这一战略财务举措旨在分散CVS Health的资金来源并延长其债务到期日。
CVS Health Corporation已于2024年5月7日成功对一系列优先票据进行了定价,总价值为50亿美元。此次发行包括将于2029年到期的10亿美元5.400%的优先票据,2031年到期的10亿美元5.550%的优先票据,2034年到期的12.5亿美元5.700%的优先票据,2044年到期的7.5亿美元6.000%的优先票据,以及2054年到期的10亿美元6.050%的优先票据。这些票据的定价接近其本金,并将从2024年12月1日起支付半年利息。这些票据的到期日为2029年6月1日至2054年6月1日。CVS Health为这些票据提供了可选的赎回条款,允许公司在某些条件下在到期日之前赎回票据。此次发行由包括美银证券公司、巴克莱资本公司等在内的银行财团管理。这些票据被穆迪评为Baa2,标准普尔将BBB评为Baa2。这一战略财务举措旨在分散CVS Health的资金来源并延长其债务到期日。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息